Moderna Secures Up to $750M in Funding from Blackstone to Advance Flu Program

Moderna announced during its annual Vaccines Day event on Wednesday that it has secured up to $750 million in funding from asset management firm Blackstone Life Sciences to advance its mRNA-based flu program.